AlzeCure raises SEK 30.1M in oversubscribed rights issue after Lilly deal
What's the deal? AlzeCure PharmaDealroom has a profile for this one. Try Dealroom →, a Swedish drug developer, has raised roughly SEK 30.1 million ($3.1 million) in a fully secured rights issue completed on June 30, 2026. ABG Sundal CollierDealroom has a profile for this one. Try Dealroom → acted as sole global coordinator.
Why now? The raise follows two licensing deals in quick succession: AlzeCure out-licensed Alzstatin to Eli LillyDealroom has a profile for this one. Try Dealroom → and NeuroRestore to QuantumCell ApS. The company says that momentum underpinned the issue.
The response: The offering was heavily oversubscribed at about 329%, which AlzeCure attributes to investor confidence in its strategy.
What's the endgame? AlzeCure develops small-molecule drug candidates for central nervous system diseases, spanning Alzheimer's disease and pain. It plans to use net proceeds to accelerate its pain projects while advancing its Alzheimer's programmes with partners.
The signal: A small raise landing at more than three times demand — on the back of a big-pharma licensing deal — points to how out-licensing can reset investor sentiment for early-stage biotech.
Read more: abgsc.com
Image credit: Generated with Gemini
